Safety and Efficacy Study of CF101 to Treat Psoriasis
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This study will test the hypothesis that CF101, which is under development to treat other
immune-mediated inflammatory diseases, will provide clinical benefits in the treatment of
chronic plaque psoriasis. Patients with psoriasis who qualify for the study will be treated
every 12 hours (q12h) with CF101 capsules, or placebo capsules, for 12 weeks. The safety of
treatment will be carefully assessed through clinical and laboratory monitoring. The effect
of treatment on psoriasis will be evaluated through standard techniques of examination and
measurement of the severity of skin involvement.